<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Inducible NO synthase (NOS)-derived <z:chebi fb="0" ids="25941">peroxynitrite</z:chebi> (<z:chebi fb="0" ids="29330">ONOO</z:chebi>-) during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion contributes to ischemic brain injury </plain></SENT>
<SENT sid="1" pm="."><plain>However, inducible NOS (iNOS) regulation in <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> remains unknown </plain></SENT>
<SENT sid="2" pm="."><plain>Tetrahydrobiopterin (<z:chebi fb="5" ids="30157">BH4</z:chebi>) is an essential cofactor for NOS activity </plain></SENT>
<SENT sid="3" pm="."><plain>The present study tested the hypothesis that inhibition of endogenous <z:chebi fb="5" ids="30157">BH4</z:chebi> rate-limiting enzyme <z:chebi fb="11" ids="15996">GTP</z:chebi> cyclohydrolase I (GTPCH I), and thus <z:chebi fb="5" ids="30157">BH4</z:chebi> synthesis, reduces <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> via inhibiting iNOS and <z:chebi fb="0" ids="29330">ONOO</z:chebi>- in transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> (2 hours) was created in adult male Sprague-Dawley rats (250 to 300 g) by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="5" pm="."><plain>Rats were treated 12 hours before MCAO with vehicle or diamino-6-<z:chebi fb="0" ids="38340">hydroxypyrimidine</z:chebi> (DAHP; 0.5 g/kg IP), a selective GTPCH I inhibitor </plain></SENT>
<SENT sid="6" pm="."><plain>Brains were harvested 24 hours after reperfusion for assays of <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) permeability, GTPCH I activity, <z:chebi fb="5" ids="30157">BH4</z:chebi> levels, GTPCH I and NOS <z:chebi fb="2" ids="33699">mRNA</z:chebi>, protein expression, and <z:chebi fb="1" ids="18421">superoxide</z:chebi> <z:chebi fb="5" ids="22563">anion</z:chebi> (O2*-) and <z:chebi fb="0" ids="29330">ONOO</z:chebi>- levels </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Endogenous GTPCH I activity, <z:chebi fb="5" ids="30157">BH4</z:chebi> levels, iNOS activity, and (O2*- and <z:chebi fb="0" ids="29330">ONOO</z:chebi>- levels were <z:hpo ids='HP_0000001'>all</z:hpo> augmented after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion </plain></SENT>
<SENT sid="8" pm="."><plain>DAHP treatment significantly reduced GTPCH I activity, resulting in decreased <z:chebi fb="5" ids="30157">BH4</z:chebi> levels, iNOS activity, and <z:chebi fb="0" ids="29330">ONOO</z:chebi>- levels </plain></SENT>
<SENT sid="9" pm="."><plain>Consequently, DAHP treatment significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> size compared with the nontreated group (22.3+/-5.6 versus 38.3+/-7.4%; n=6; P&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>Similarly, <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability was significantly reduced after DAHP pretreatment compared with the control group (4.11+/-0.22 versus 7.78+/-0.44 microg/g tissue; n=5; P&lt;0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: These results demonstrate that blockade of endogenous brain <z:chebi fb="5" ids="30157">BH4</z:chebi> synthesis attenuates <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> via inhibiting iNOS and <z:chebi fb="0" ids="29330">ONOO</z:chebi>-, which may provide a mechanistic basis of novel therapeutic strategies for <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>